- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 10.39 Employment Letter with Dominick Colangelo
- 10.40 Employment Letter with Antonius Bunt
- 12.1 Statement Re: Computation of Ratios
- 23.1 Consent of Ernst & Young LLP
- 31.1 Certification of Chief Executive Officer Pursuant to Section 302
- 31.2 Certification of Chief Financial Officer Pursuant to Section 302
- 32.1 Certification of Chief Executive Officer Pursuant to Section 906
- 32.2 Certification of Chief Financial Officer Pursuant to Section 906
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (File No.’s 2-77846, No. 2-81123, No. 2-95446, No. 33-12633, No. 33-27885, No. 0-10824, No. 33-45432, No. 33-75136, No. 333-15935, No. 333-49069, No. 333-30920, No. 333-39390, No. 333-92951, No. 333-32614, No. 333-58274, No. 333-112810, No. 333-106563 and No. 333-97139) of Oscient Pharmaceuticals Corporation of our reports dated March 10, 2005, with respect to the consolidated financial statements of Oscient Pharmaceuticals Corporation as of and for the year ended December 31, 2004, Oscient Pharmaceuticals Corporation’s management’s assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Oscient Pharmaceuticals Corporation as of December 31, 2004, included in this Annual Report (Form 10-K) for the year ended December 31, 2004.
/S/ ERNST & YOUNG LLP
Boston, Massachusetts
March 14, 2005